|
1
|
Han S, Liu Y, Cai SJ, Qian M, Ding J,
Larion M, Gilbert MR and Yang C: IDH mutation in glioma: Molecular
mechanisms and potential therapeutic targets. Br J Cancer.
122:1580–1589. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Shi J, Zuo H, Ni L, Xia L, Zhao L, Gong M,
Nie D, Gong P, Cui D, Shi W and Chen J: An IDH1 mutation inhibits
growth of glioma cells via GSH depletion and ROS generation. Neurol
Sci. 35:839–845. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Komori T: The 2021 WHO classification of
tumors, 5th edition, central nervous system tumors: The 10 basic
principles. Brain Tumor Pathol. 39:47–50. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Molenaar RJ, Botman D, Smits MA, Hira VV,
van Lith SA, Stap J, Henneman P, Khurshed M, Lenting K, Mul AN, et
al: Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant
inhibitor AGI-5198. Cancer Res. 75:4790–4802. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Qing X, Shao Z, Lv X, Pu F, Gao F, Liu L
and Shi D: Anticancer effect of (S)-crizotinib on osteosarcoma
cells by targeting MTH1 and activating reactive oxygen species.
Anticancer Drugs. 29:341–352. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gad H, Koolmeister T, Jemth AS, Eshtad S,
Jacques SA, Ström CE, Svensson LM, Schultz N, Lundbäck T,
Einarsdottir BO, et al: MTH1 inhibition eradicates cancer by
preventing sanitation of the dNTP pool. Nature. 508:215–221.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bhavya B, Easwer HV, Vilanilam GC, Anand
CR, Sreelakshmi K, Urulangodi M, Rajalakshmi P, Neena I,
Padmakrishnan CJ, Menon GR, et al: MutT homolog1 has multifaceted
role in glioma and is under the apparent orchestration by hypoxia
inducible factor1 alpha. Life Sci. 264(118673)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang
P, Yu W, Li Z, Gong L, Peng Y, et al: Glioma-derived mutations in
IDH1 dominantly inhibit IDH1 catalytic activity and induce
HIF-1alpha. Science. 324:261–265. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gilbert MR, Liu Y, Neltner J, Pu H, Morris
A, Sunkara M, Pittman T, Kyprianou N and Horbinski C: Autophagy and
oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol.
127:221–233. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen L, Li X, Liu L, Yu B, Xue Y and Liu
Y: Erastin sensitizes glioblastoma cells to temozolomide by
restraining xCT and cystathionine-γ-lyase function. Oncol Rep.
33:1465–1474. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Behrend L, Henderson G and Zwacka RM:
Reactive oxygen species in oncogenic transformation. Biochem Soc
Trans. 31:1441–1444. 2003.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Reczek CR and Chandel NS: The two faces of
reactive oxygen species in cancer. Annu Rev Cancer Biol. 1:79–98.
2017.
|
|
15
|
Mohamed Yusoff AA, Zulfakhar FN, Sul'ain
MD, Idris Z and Abdullah JM: Association of the IDH1 C.395G>A
(R132H) mutation with histological type in malay brain tumors.
Asian Pac J Cancer Prev. 17:5195–5201. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bhavya B, Anand CR, Madhusoodanan UK,
Rajalakshmi P, Krishnakumar K, Easwer HV, Deepti AN and Gopala S:
To be wild or mutant: Role of isocitrate dehydrogenase 1 (IDH1) and
2-hydroxy glutarate (2-HG) in gliomagenesis and treatment outcome
in glioma. Cell Mol Neurobiol. 40:53–63. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L
and Chen J: Decreasing GSH and increasing ROS in chemosensitivity
gliomas with IDH1 mutation. Tumour Biol. 36:655–662.
2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Reiter-Brennan C, Semmler L and Klein A:
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas.
Contemp Oncol (Pozn). 22:215–222. 2018.PubMed/NCBI View Article : Google Scholar
|
